TTK Healthcare
LIMITED

TTKH:SECL:SL:122:26 July 24, 2026

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

SCRIP CODE: 507747

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra East
Mumbai 400 051

SCRIP CODE: TTKHLTCARE

Dear Sirs,

Re : Chairman's Speech – 68th Annual General Meeting of the Company – July 24, 2026

We are forwarding herewith a copy of the Chairman Speech delivered by Mr. K Shankaran, Director on behalf of the Chairman, at the 68th Annual General Meeting of our Company held today through Video Conferencing / Other Audio Visual Means (VC / OAVM).

We request you to kindly take the above document on record.

Thanking you

Yours faithfully
For TTK Healthcare Limited
Gowry A Jaishankar
Digitally signed by Gowry A Jaishankar
Date: 2026.07.24 14:38:35 +05'30'
(GOWRY A JAISHANKAR)
DGM – Legal & Company Secretary

Encl. : a/a

TTK HEALTHCARE LIMITED
Regd. Office: No.6, Cathedral Road, Chennai 600 086
CIN: L24231TN1958PLC003647 | Website: www.ttkhealthcare.com

CHAIRMAN'S SPEECH

[68th ANNUAL GENERAL MEETING – JULY 24, 2026]

Ladies and Gentlemen,

It gives me great pleasure to welcome you all to this 68th Annual General Meeting of your Company.

TRIBUTE TO LATE MR. T T JAGANNATHAN

At the outset, the Board places on record its deepest respect and appreciation to Mr T T Jagannathan, Former Chairman, who passed away on October 09, 2025. During his association with the Company nearly for four decades, he made invaluable contributions towards its growth and success. His vision, leadership and commitment will always be remembered with great respect and gratitude and the Board pays its heartfelt tribute to his enduring legacy.

FINANCIAL YEAR 2025-26:

The Annual Report for the year has already been circulated. I would like to touch upon the salient features of the Company's performance during the year under review.

Financial Highlights:

- Revenue from Operations amounted to Rs.857.28 crores as against the previous year's figure of Rs.801.49 crores, with a growth of around 7%.
- The Pre-tax Profit after Exceptional Items stood at Rs.82.56 crores [Previous Year: Rs.108.33 crores].

  The Exceptional Items for the year amounted to negative of Rs.407.45 lakhs [Previous Year: Rs.1,390.66 lakhs].

  The drop in profit was mainly on account of lower profit reported by Protective Devices Division due to loss of Institutional / Tender business particularly from USAID.
- Earnings per Share (EPS) was Rs.46.48 (Previous Year: Rs.57.79).
- Your Company carries a free Cash Balance of around Rs.900 crores, as at March 31, 2026.

SALE OF EVA AND GOOD HOME BRANDS:

EVA and Good Home, an integral part of our Consumer Products portfolio are earning the trust of consumers for many years. Sustained efforts of the Company and huge investments on these two brands have brought the combined turnover of Rs.148 crores for the FY 2025-26.

As part of the strategic direction for Consumer Products Division and also considering the current market scenario, the Board of Directors thought it would be a good idea to divest these brands.

Accordingly, definitive agreements have been entered into with M/s Wipro Enterprises Private Limited for sale of these two brands at a consideration of Rs.256 crores plus applicable GST, with the closing of the transaction contemplated thereunder being subject to the fulfilment of the ‘conditions precedent’ that are customary in such transactions.

Your Directors believe Wipro is well positioned to take these brands to the next stage of growth supported by its strong FMCG capabilities and proven track record of nurturing the acquired brands.

BUSINESSWISE PERFORMANCE:

Let me now provide a quick brief on the performance of the various businesses of the Company during 2025-26 and also the plans for the year 2026-27.

(1) **Consumer Products Business (CPD)** reported a static performance.

The year 2025–26 was challenging for ***Woodward’s Gripe Water* (*WGW*)**, with volume declines, particularly in Southern markets. However, e-Commerce and Modern Trade delivered strong growth though on a lower base.

To strengthen brand momentum, the Company nationally launched the **“I Am Woodward’s Baby”** campaign, reinforcing product safety and its legacy of trust, supported by regional activations in Tamil Nadu and the Western markets.

The launch of **Woodward’s Tummy Roll-On** on e-Commerce platforms also marked the brand’s entry into the “Care” segment, strengthening its positioning as a **Tummy Care Expert**.

For 2026–27, the strategy focuses on enhancing brand relevance and driving earlier adoption among new-age parents through: (i) a new communication platform educating parents on infant tummy care and the role of gripe water, on the basis of the insights gathered through a national survey; (ii) expansion of the “Care” portfolio with the proposed launch of **Tummy Tonic** in Tamil Nadu, supported by media campaigns and paediatrician engagement; and (iii) wider distribution of **Tummy Roll-On** through quick-commerce and specialty pharmacy channels.

These initiatives support the Company’s vision of evolving Woodward’s from a single-product brand into a comprehensive Tummy Care expert while preserving its long-standing legacy of trust.

Skore delivered resilient performance during the year under review, achieving 6% value growth while maintaining volumes despite challenges in traditional trade. E-commerce remained a key growth driver, delivering strong performance.

For 2026–27, the focus will be on accelerating growth through premium product launches across traditional trade and e-commerce channels, supported by sustained brand-building campaigns to enhance consumer awareness and brand salience.

(2) **Animal Welfare Business (AWD)** reported a revenue growth of around 12%, driven by a stronger second-half performance.

While Bovianim, Gallus and Aquanim recorded a robust growth, Companim grew only by 5% amid market-related challenges.

For 2026–27, the Division will focus on strengthening its flagship brands through farm programmes and KOL engagement, accelerating growth by bifurcating the Bovianim business, revitalising the Companim portfolio, expanding e-commerce, quick-commerce and retail channels, and driving incremental revenue through targeted new product launches.

(3) **Medical Devices Business:**

Heart Valve Division reported a revenue growth of around 2%. While supplies of CardiaMed Bi-Leaflet Valves were impacted by the Russia–Ukraine conflict, limited imports from the Russian manufacturer helped address availability.

Considering this, the Division will focus on increasing volumes of TTK Chitra Heart Valves.

The single-centric pilot study of the improved TC2 TTK Chitra Titanium Heart Valve has been completed, with encouraging three-year follow-up results. Subject to funding and regulatory approvals, the Company plans to commence pivotal studies involving around 400 patients.

Ortho Division reported a strong revenue growth of 27%, supported by robust performance across key markets and expansion into new regions. The pilot launch of the **Citius** Fixed Bearing Knee Implant received an encouraging response, while TiN-coated implants and the Hip Implants portfolio delivered healthy growth.

For 2026–27, the Division will focus on the nationwide rollout of **Citius**, expansion of the field force, launch of the Revision Hip Implant System and TiN-Coated **Fortius** Fixed Bearing Knee Implants, enhancement of manufacturing capacity and automation, and development of new products, including Ankle and Unicondylar Knee Replacement Implants.

(4) **Protective Devices Business** reported a revenue growth of around 5%. Despite initial challenges arising from the cessation of USAID business and the absence of a long-term agreement with UNFPA, the Division recovered through new customer additions and ended the year on a positive note.

The Company retained its WHO-UNFPA pre-qualified supplier status, expanded its customer base through strong quality standards, initiated product registrations in multiple countries, and continued to pursue export opportunities and sustainability initiatives.

For 2026–27, the focus will be on strengthening contract manufacturing partnerships, expanding into new geographies, increasing supplies to new customers, introducing innovative products, and commencing lubricant manufacturing at the Virudhunagar facility.

(5) **The Pleasure Products Business** comprises Skore Pleasure Products, MsChief, and Love Depot, strengthening the Company's presence across the male and female sexual wellness categories. FY 2025–26 was a year of consolidation, capability building and portfolio expansion.

Skore Pleasure Products delivered healthy growth, driven by strong e-commerce and quick-commerce performance, particularly in accessories and lubricants. Continued portfolio expansion and category-first innovations reinforced its leadership, while exclusive product launches through Love Depot validated the potential of innovation-led offerings. The focus for FY 2026–27 will be on portfolio expansion, product innovation and strengthening digital brand salience.

MsChief recorded strong growth, led by e-commerce and quick-commerce channels, while establishing an initial presence in modern trade. The year focused on strengthening the portfolio and brand architecture. In FY 2026–27, the brand will accelerate growth through increased brand investments, creator-led marketing, the launch of **MsChief 2.0**, and expansion into premium product ranges.

Love Depot reported nominal revenue growth while significantly improving marketing efficiency. Growth in organic traffic, repeat customers and successful launches of exclusive products reinforced its role as the Division's innovation and incubation platform.

Overall, the Pleasure Products Business strengthened the Company's position in the sexual wellness category and will focus on accelerating growth in FY 2026–27 through innovation, brand building and deeper consumer engagement.

(6) **Foods Business** reported a revenue growth of 14%. Four new products developed by the Hosakote R&D Centre were successfully commercialised, with an increased focus on protein-rich and health-oriented offerings. The Jaipur and Hosakote plants also received Non-GMO Project Verified Certification for one product each.

The Division continued to enhance operational efficiency through TPM, capacity expansion, productivity improvements and cost-saving initiatives across the value chain.

For 2026–27, the focus will be on maximising production at both plants, optimising the product mix through exports and institutional business to improve profitability, and launching innovative, differentiated products to drive growth and margins.

DIVIDEND:

Your Directors recommend a dividend of Rs.10.00 per share (i.e.) 100%. [Previous Year – Rs.10.00 per share (i.e.) 100%].

OUTLOOK 2026-27:

But for the prevailing Geopolitical instability and also the West Asia Crisis, the outlook for your Company as a whole for 2026-27, appears positive considering the above developments and initiatives.

ACKNOWLEDGEMENT:

I acknowledge the valuable contributions of Banks, Business Associates, Shareholders and Employees at all levels who have supported the Company in all its endeavours.

Thank you.